Novel fluoroprostacyclin analogs with modified cycloalkylenyl chains. Highly potent and orally active anti-anginal agents.
Novel fluoroprostacyclin analogs (1a-f) have been synthesized and pharmacologically evaluated. Compounds 1a-c given intravenously or orally showed potent and long-lasting anti-anginal activities in an animal model.
Matsumura
Y
Y
Research Center, Asahi Glass Co., Ltd. Yokohama, Japan.
Asai
T
T
Shimada
T
T
Nakayama
T
T
Urushihara
M
M
Morizawa
Y
Y
Yasuda
A
A
Yamamoto
T
T
Fujitani
B
B
Hosoki
K
K
D000284:Administration, Oral; D000787:Angina Pectoris / Q000188:drug therapy*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004562:Electrocardiography / Q000187:drug effects; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005461:Fluorine / Q000737:chemistry; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D016285:Iloprost / Q000008:administration & dosage / Q000494:pharmacology; D007275:Injections, Intravenous; D010974:Platelet Aggregation / Q000187:drug effects*; D051381:Rats; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014667:Vasopressins / Q000633:toxicity
D014667:Vasopressins; D005461:Fluorine; D011464:Epoprostenol; D016285:Iloprost